Article thumbnail

Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients

By Emily L. Heil, Mary L. Townsend, Kenneth Shipp, Amy Clarke and Melissa D. Johnson


Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI naïve at their first clinic visit and were initiated on an NNRTI- and/or PI-based antiretroviral regimen. Patients were excluded if they had active or chronic hepatitis B virus (HBV). The primary objective was to determine the overall incidence of severe hepatotoxicity. Results. Fifty-six of the 544 patients identified met inclusion criteria. The incidence of severe hepatotoxicity was 10.7% (6/56 patients). Severe hepatotoxicity occurred with efavirenz (N = 2), nevirapine (N = 1), indinavir (N = 1), nelfinavir (N = 1), and saquinavir/ritonavir (N = 1). Conclusion. The incidence of severe hepatotoxicity appears to be low in this retrospective analysis of HIV/HCV co-infected patients receiving a PI-and/or NNRTI-based regimen

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis
  2. (2000). Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy
  3. (2003). Hepatitis C in the HIVinfected person,”
  4. (2000). Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus,”
  5. (2002). Hepatotoxicity associated with nevirapine orefavirenz-containingantiretroviraltherapy:roleofhepatitis
  6. (2005). Hepatotoxicity of antiretrovirals: incidence, mechanisms and management,”
  7. (2004). Liver injury during highly active antiretroviral therapy: the effect of hepatitis
  8. (2000). S u l k o w s k i ,D .L .T h o m a s ,R .E .C h a i s s o n ,a n dR .D . Moore, “Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection,”
  9. (1996). Trials Group, Table of Grading Severity of Adult Adverse Experiences,
  10. (2001). u˜ n e z ,R .L a n a ,J .L .M e n d o z a ,L .M a r t ´